Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort-Reference-Cited by-同舟云学术

Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

Published:2019-08-30 Issue:8 Volume:14 Page:e0221231
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Pérez Ana Belén^ORCID,Chueca Natalia,Macías Juan^ORCID,Pineda Juan Antonio,Salmerón Javier,Rivero-Juárez Antonio,Hidalgo-Tenorio Carmen,Espinosa María Dolores,Téllez Francisco^ORCID,Von-Wichmann Miguel Ángel,Omar Mohamed,Santos Jesús,Hernández-Quero José,Antón José Joaquin,Collado Antonio,Lozano Ana Belén,García-Deltoro Miguel,Casado Marta,Pascasio Juan Manuel,Selfa Aida,Rosales José Miguel,De la Iglesia Alberto,Arenas Juan Ignacio,García-Bujalance Silvia,Ríos María José,Bernal Enrique,Martínez Onofre,García-Herola Antonio,Vélez Mónica,Rincón Pilar,García Federico

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.;Polaris Observatory HCV Collaborators;Lancet Gastroenterol Hepatol,2017

2. Treatment of hepatitis C: Results in real life;C. Hézode;Liver International,2018

3. AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org. Accessed June 2018.

4. EASL Recommendations on Treatment of Hepatitis C 2018;European Association for the Study of the Liver;J Hepatol,2018

5. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus;N Ogata;Proceedings of the National Academy of Sciences of the United States of America,1991

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral Hepatitis;Manson's Tropical Diseases;2024

2. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks;Journal of Clinical Virology Plus;2023-06

3. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

4. Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens;Open Forum Infectious Diseases;2021-09-30

5. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions;World Journal of Hepatology;2021-09-27